China's CSPC Pharmaceutical H1 revenue rises on finished drug business growth

CSPC PHARMACEUTICAL

20/08/2026 05:30

Overview
China pharmaceutical maker's H1 revenue rose 40% yr/yr, driven by finished drugs growth
Net profit attributable to shareholders for H1 rose 139% yr/yr
Company utilized HK$321 mln for share buybacks in H1

Outlook
Company did not provide specific financial guidance or forecasts for future periods in press release

Result Drivers
FINISHED DRUGS GROWTH - Finished drugs revenue rose 56.7% yr/yr, driving overall revenue growth
BULK PRODUCTS DECLINE - Bulk products revenue fell 20% yr/yr, partially offsetting gains in finished drugs
FUNCTIONAL FOOD WEAKNESS - Functional food and others revenue fell 8.2% yr/yr

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 18.59 bln
 
H1 Net Income Attributable
 
RMB 6.09 bln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 3 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for CSPC PHARMACEUTICAL GROUP LIMITED is HK$10.90, about 25.5% above its August 19 closing price of HK$8.69
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 14 three months ago

Reuters Recommended Reads
Aug 19 - China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up
Aug 19 - China's top drugmaker Hengrui sees profit growth squeezed by bulk-buying programs
Aug 17 - China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)